Ironwood Pharmaceuticals (IRWD) Total Non-Current Liabilities (2011 - 2026)

Ironwood Pharmaceuticals (IRWD) has 15 years of Total Non-Current Liabilities data on file, last reported at $413.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 33.39% year-over-year to $413.4 million; the trailing twelve-month figure through Mar 2026 stood at $413.4 million (up 33.39% YoY), and the FY2025 full-year result was $375.3 million, up 12.42% from the prior year.
• Total Non-Current Liabilities improved to $413.4 million in Q1 2026, from $375.3 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $1.1 billion in Q1 2023 to a low of $309.9 million in Q1 2025.
• A 5-year average of $592.2 million and a median of $413.4 million in 2026 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities surged 80.4% in 2022 and sank 64.2% in 2024, its largest moves.
• Tracing IRWD's Total Non-Current Liabilities over 5 years: stood at $1.1 billion in 2022, then sank by 59.42% to $442.7 million in 2023, then declined by 24.59% to $333.8 million in 2024, then advanced by 12.42% to $375.3 million in 2025, then advanced by 10.16% to $413.4 million in 2026.
• Business Quant data shows IRWD's Total Non-Current Liabilities at $413.4 million in Q1 2026, $375.3 million in Q4 2025, and $373.8 million in Q3 2025.